Other Information.
−Removed: Trading Plans or Rule 10b5-1 Trading Plans
−Removed: During the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
−Removed: Date of Adoption/
−Removed: Type of Trading Arrangement
−Removed: Expiration Date
−Removed: Total Shares of Common Stock to be Sold***
−Removed: Non-Rule 10b5-1**
−Removed: Sean Bohen, M.D., Ph.D.
−Removed: President and Chief Executive Officer
−Removed: March 3, 2026
−Removed: Up to 705,000
−Removed: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
−Removed: ** "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
−Removed: *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement .
−Removed: The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.
+Added: During the fiscal quarter ended June 30, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as such terms are defined in Item 408(a) of Regulation S-K under the Exchange Act .
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws.
−Removed: Third Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated January 11, 2026.
−Removed: Separation and Consulting Agreement by and between the Company and Shane Kovacs.
Olema Pharmaceuticals, Inc.
1 unchanged sentence
Lease Agreement, dated April 27, 2026, between KR Oyster Point II, LLC and Olema Pharmaceuticals, Inc.
+Added: Fourth Amendment to Loan and Security Agreement, dated July 1, 2026, between Silicon Valley Bank and Olema Pharmaceuticals, Inc.
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
6 unchanged sentences
The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated
−Removed: by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material.
1 unchanged sentence
Olema Pharmaceuticals, Inc.
+Added: August 10, 2026
/s/ Sean Bohen, M.D., Ph.D.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.